VERU-100 is a peptide commercialized by Veru, with a leading Phase II program in Hormone-Sensitive Prostate Cancer. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of VERU-100’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for VERU-100 is expected to reach an annual total of $20 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

VERU-100 Overview

VERU-100 is under development for the treatment of hormone sensitive prostate cancer. It is administered as a subcutaneous three months depot. It is a long-acting GnRH antagonist peptide. It acts by targeting gonadotropin-releasing hormone (GnRH) receptor.

Veru Overview

Veru is a biopharmaceutical company that develop novel medicines for the management of breast cancer and prostate cancer. The company is headquartered in United States.

The company reported revenues of (US Dollars) US$39.4 million for the fiscal year ended September 2022 (FY2022), a decrease of 35.8% over FY2021. The operating loss of the company was US$83.2 million in FY2022, compared to an operating profit of US$13 million in FY2021. The net loss of the company was US$83.8 million in FY2022, compared to a net profit of US$7.4 million in FY2021. The company reported revenues of US$2.5 million for the first quarter ended December 2022, a decrease of 3.1% over the previous quarter.

For a complete picture of VERU-100’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.